Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, openlabel, randomised, phase 3 study - Zhou, C; Wu, YL; Chen, G (Lancet Oncol, 2011)
et al.